BACKGROUND: In this phase 1 trial, the authors evaluated sunitinib combined with radiation therapy (RT) for the treatment of primary or metastatic central nervous system (CNS) malignancies. METHODS: Eligible patients had CNS malignancies that required a (minimum) 2-week course of RT. Sunitinib (37.5 mg) was administered daily for the duration of RT with optional treatment extension of 1 month. Urine was collected at 3 time points for correlative biomarker studies. The primary endpoint was acute toxicity defined according to Common Toxicity Criteria version 3. RESULTS: Fifteen patients were enrolled (12 with CNS metastasis and 3 with primary tumors). RT doses ranged from 14 Gray (Gy) to 70 Gy (1.8-3.5 Gy per fraction). Acute toxicities included hematologic, nausea, hyperglycemia, fatigue, hypocalcemia, and diarrhea. Six patients (40%) developed grade ≤ 2 toxicities. Grade 3 toxicities occurred in 7 patients (47%) and included hematologic toxicity, fatigue, deep vein thrombosis, dysphasia, hyperglycemia, and hyponatremia. No grade 3 through 5 hypertensive events or intracerebral hemorrhages occurred. Two grade 5 adverse events attributed to disease progression occurred. The median follow-up was 34.2 months. Two patients (13%) achieved a partial response, 9 patients (60%) had stable disease, and 2 patients (13%) patients had progressive disease. The 6-month progression-free survival rate for patients who had brain metastasis was 58%. Grade 3 hematologic toxicity was correlated with greater changes in vascular endothelial growth factor levels changes between baseline and the completion of RT. CONCLUSIONS: Continuous 37.5-mg sunitinib combined with RT in patients who had CNS malignancies yielded acceptable toxicities and adverse events. The current results indicated that changes in urine vascular endothelial growth factor levels are associated with hematologic toxicity, and this association should be analyzed in a larger cohort. The feasibility, safety, and early response results warrant a phase 2 trial.
BACKGROUND: In this phase 1 trial, the authors evaluated sunitinib combined with radiation therapy (RT) for the treatment of primary or metastatic central nervous system (CNS) malignancies. METHODS: Eligible patients had CNS malignancies that required a (minimum) 2-week course of RT. Sunitinib (37.5 mg) was administered daily for the duration of RT with optional treatment extension of 1 month. Urine was collected at 3 time points for correlative biomarker studies. The primary endpoint was acute toxicity defined according to Common Toxicity Criteria version 3. RESULTS: Fifteen patients were enrolled (12 with CNS metastasis and 3 with primary tumors). RT doses ranged from 14 Gray (Gy) to 70 Gy (1.8-3.5 Gy per fraction). Acute toxicities included hematologic, nausea, hyperglycemia, fatigue, hypocalcemia, and diarrhea. Six patients (40%) developed grade ≤ 2 toxicities. Grade 3 toxicities occurred in 7 patients (47%) and included hematologic toxicity, fatigue, deep vein thrombosis, dysphasia, hyperglycemia, and hyponatremia. No grade 3 through 5 hypertensive events or intracerebral hemorrhages occurred. Two grade 5 adverse events attributed to disease progression occurred. The median follow-up was 34.2 months. Two patients (13%) achieved a partial response, 9 patients (60%) had stable disease, and 2 patients (13%) patients had progressive disease. The 6-month progression-free survival rate for patients who had brain metastasis was 58%. Grade 3 hematologic toxicity was correlated with greater changes in vascular endothelial growth factor levels changes between baseline and the completion of RT. CONCLUSIONS: Continuous 37.5-mg sunitinib combined with RT in patients who had CNS malignancies yielded acceptable toxicities and adverse events. The current results indicated that changes in urine vascular endothelial growth factor levels are associated with hematologic toxicity, and this association should be analyzed in a larger cohort. The feasibility, safety, and early response results warrant a phase 2 trial.
Authors: S George; J Y Blay; P G Casali; A Le Cesne; P Stephenson; S E Deprimo; C S Harmon; C N J Law; J A Morgan; I Ray-Coquard; V Tassell; D P Cohen; G D Demetri Journal: Eur J Cancer Date: 2009-03-11 Impact factor: 9.162
Authors: Jonathan P S Knisely; Brian Berkey; Arnab Chakravarti; Al W K Yung; Walter J Curran; H Ian Robins; Benjamin Movsas; David G Brachman; Randall H Henderson; Minesh P Mehta Journal: Int J Radiat Oncol Biol Phys Date: 2007-12-31 Impact factor: 7.038
Authors: Johnny Kao; Stuart Packer; Ha Linh Vu; Myron E Schwartz; Max W Sung; Richard G Stock; Yeh-Chi Lo; Delphine Huang; Shu-Hsia Chen; Jamie A Cesaretti Journal: Cancer Date: 2009-08-01 Impact factor: 6.860
Authors: Suzanne George; Priscilla Merriam; Robert G Maki; Annick D Van den Abbeele; Jeffrey T Yap; Timothy Akhurst; David C Harmon; Gauri Bhuchar; Margaret M O'Mara; David R D'Adamo; Jeffrey Morgan; Gary K Schwartz; Andrew J Wagner; James E Butrynski; George D Demetri; Mary L Keohan Journal: J Clin Oncol Date: 2009-05-18 Impact factor: 44.544
Authors: Stefanie Milker-Zabel; Angelika Zabel-du Bois; Gholamreza Ranai; Thuy Trinh; Andreas Unterberg; Jürgen Debus; Kenneth E Lipson; Amir Abdollahi; Peter E Huber Journal: Int J Radiat Oncol Biol Phys Date: 2008-01-30 Impact factor: 7.038
Authors: Sophie de Boüard; Paulette Herlin; James G Christensen; Edwige Lemoisson; Pascal Gauduchon; Eric Raymond; Jean-Sébastien Guillamo Journal: Neuro Oncol Date: 2007-07-10 Impact factor: 12.300
Authors: Samuel E Deprimo; Carlo L Bello; John Smeraglia; Charles M Baum; Dominic Spinella; Brian I Rini; M Dror Michaelson; Robert J Motzer Journal: J Transl Med Date: 2007-07-02 Impact factor: 5.531
Authors: Maikel Verduin; Jaap D Zindler; Hanneke M A Martinussen; Rob L H Jansen; Sander Croes; Lizza E L Hendriks; Danielle B P Eekers; Ann Hoeben Journal: Oncologist Date: 2017-02-06
Authors: Philip Wong; Peter Houghton; David G Kirsch; Steven E Finkelstein; Arta M Monjazeb; Meng Xu-Welliver; Adam P Dicker; Mansoor Ahmed; Bhadrasain Vikram; Beverly A Teicher; C Norman Coleman; Mitchell Machtay; Walter J Curran; Dian Wang Journal: J Natl Cancer Inst Date: 2014-10-18 Impact factor: 13.506
Authors: C S Higano; J Berlin; M Gordon; P LoRusso; S Tang; A Dontabhaktuni; J D Schwartz; J Cosaert; J M Mehnert Journal: Invest New Drugs Date: 2015-03-07 Impact factor: 3.651
Authors: Esther A Kleibeuker; Matthijs A Ten Hooven; Henk M Verheul; Ben J Slotman; Victor L Thijssen Journal: Angiogenesis Date: 2015-07-23 Impact factor: 9.596